Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-13 5:20 pm Unchanged | 2023-12-11 | 13D | Keros Therapeutics, Inc. KROS | ORBIMED ADVISORS LLC | 1,268,734 4.200% | 0 (Unchanged) | Filing History |
| 2023-02-14 09:53 am Sale | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | Deep Track Capital, LP | 0 0.000% | -1,300,000 (Position Closed) | Filing History |
| 2023-02-13 10:13 am Purchase | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | Alkeon Capital Management LLC | 1,392,402 5.100% | 1,392,402 (New Position) | Filing History |
| 2023-02-09 12:48 pm Purchase | 2023-02-09 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,679,089 13.357% | 174,291 (+4.97%) | Filing History |
| 2023-02-07 11:06 am Purchase | 2022-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,638,326 5.900% | 351,800 (+27.34%) | Filing History |
| 2023-02-02 2:23 pm Sale | 2023-01-26 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,371,074 4.980% | -441,241 (-24.35%) | Filing History |
| 2022-11-07 4:25 pm Unchanged | 2022-11-03 | 13D | Keros Therapeutics, Inc. KROS | ORBIMED ADVISORS LLC | 1,268,734 4.600% | 0 (Unchanged) | Filing History |
| 2022-04-12 06:18 am Unchanged | 2022-04-11 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,812,315 7.550% | 0 (Unchanged) | Filing History |
| 2022-04-11 4:57 pm Sale | 2022-04-11 | 13G | Keros Therapeutics, Inc. KROS | Moshe Arkin | 1,812,315 7.550% | -223,825 (-10.99%) | Filing History |
| 2022-02-14 08:58 am Purchase | 2021-12-31 | 13G | Keros Therapeutics, Inc. KROS | Deep Track Capital, LP | 1,300,000 5.500% | 11,276 (+0.87%) | Filing History |
| 2022-02-11 3:13 pm Sale | 2021-12-31 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV, L.P. | 0 0.000% | -1,412,705 (Position Closed) | Filing History |
| 2022-02-09 09:22 am Purchase | 2022-02-08 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 3,504,798 14.978% | 860,178 (+32.53%) | Filing History |
| 2022-02-03 4:29 pm Purchase | 2021-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,286,526 5.500% | 87,325 (+7.28%) | Filing History |
| 2021-12-30 4:37 pm Purchase | 2021-12-29 | 13G | Keros Therapeutics, Inc. KROS | Deep Track Capital, LP | 1,288,724 5.450% | 1,288,724 (New Position) | Filing History |
| 2021-02-16 4:00 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | Logos Global Master Fund LP | 450,000 1.900% | 450,000 (New Position) | Filing History |
| 2021-02-16 10:56 am Sale | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | Foresite Capital Fund IV, L.P. | 1,412,705 6.100% | -15,366 (-1.08%) | Filing History |
| 2021-02-10 4:48 pm Sale | 2021-01-31 | 13G | Keros Therapeutics, Inc. KROS | RA Capital Management, L.P. | 0 0.000% | -1,875,000 (Position Closed) | Filing History |
| 2021-02-10 4:31 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | RA Capital Management, L.P. | 1,875,000 8.100% | 1,875,000 (New Position) | Filing History |
| 2021-02-08 10:25 am Sale | 2021-02-05 | 13G | Keros Therapeutics, Inc. KROS | FMR LLC | 2,644,620 11.411% | -381,261 (-12.60%) | Filing History |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Keros Therapeutics, Inc. KROS | BlackRock Inc. BLK | 1,199,201 5.200% | 1,199,201 (New Position) | Filing History |